Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Mallinckrodt
McKinsey
Express Scripts
AstraZeneca

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OXYBUTYNIN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Oxybutynin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00170768 Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over Completed Novartis Phase 2 2005-02-01 The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
NCT00175123 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status Aarhus University Hospital Phase 4 2005-05-01 The purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. The trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. The purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. The aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. The hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder.
NCT00175123 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status University of Aarhus Phase 4 2005-05-01 The purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. The trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. The purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. The aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. The hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder.
NCT00223821 Enhancing Conservative Treatment for Urge Incontinence Completed VA Office of Research and Development N/A 2003-09-01 The primary objective of this project is to evaluate whether enhancing drug therapy with components of behavioral training, including pelvic floor muscle rehabilitation, results in better outcomes than drug therapy alone for urge incontinence in community-dwelling women.
NCT00224016 Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition Completed Watson Pharmaceuticals Phase 4 2004-12-01 This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder.
NCT00224029 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed Watson Pharmaceuticals Phase 4 2004-12-01 This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oxybutynin

Condition Name

Condition Name for Oxybutynin
Intervention Trials
Overactive Bladder 18
Healthy 7
Hyperhidrosis 7
Urinary Incontinence 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Oxybutynin
Intervention Trials
Urinary Bladder, Overactive 25
Urinary Incontinence 12
Enuresis 12
Hyperhidrosis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Oxybutynin

Trials by Country

Trials by Country for Oxybutynin
Location Trials
United States 167
Japan 13
Canada 11
Spain 6
Brazil 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Oxybutynin
Location Trials
North Carolina 9
California 9
Georgia 8
Michigan 8
Ohio 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Oxybutynin

Clinical Trial Phase

Clinical Trial Phase for Oxybutynin
Clinical Trial Phase Trials
Phase 4 24
Phase 3 22
Phase 2/Phase 3 1
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Oxybutynin
Clinical Trial Phase Trials
Completed 47
Recruiting 10
Not yet recruiting 8
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Oxybutynin

Sponsor Name

Sponsor Name for Oxybutynin
Sponsor Trials
Watson Pharmaceuticals 7
Pfizer 6
Mylan Pharmaceuticals 6
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Oxybutynin
Sponsor Trials
Other 54
Industry 42
U.S. Fed 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
McKesson
McKinsey
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.